Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628095 · ClinicalTrials.gov registry record · Phase 2
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00628095 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 100 participants.
The verdict
NCT00628095, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis
Interventions
- DRUG Placebo
- DRUG CE-224,535
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-04-07 |
| Est. Completion | 2009-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00628095
The ClinicalTrials.gov registry entry for NCT00628095 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00628095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00628095 about?
NCT00628095 is a clinical study titled "Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate". CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug wi...
What is the current status of trial NCT00628095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2008-04-07. Estimated completion is 2009-02-04.
What interventions are being tested in trial NCT00628095?
The interventions under investigation include: Placebo (DRUG), CE-224,535 (DRUG).
Who is sponsoring clinical trial NCT00628095?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.